Search | Clinical Trials Finder

Conditions: Panic Disorder
Interventions: Paroxetine, Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Treatment Outcome
Interventions: Vortioxetine, Escitalopram, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more

Conditions: Depression
Interventions: S-adenosyl methione (SAMe), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Generalized Anxiety Disorder, Panic Disorder
Interventions: Niravam, SSRI/SNRI; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: PTSD, Posttraumatic Stress Disorder
Interventions: RETeval; Device
Lead sponsor: VA Puget Sound Health Care System; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obsessive-compulsive Disorder
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Transcept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more

Conditions: Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Interventions: H-Coil Deep TMS in combination with SSRIs; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Davis, California • Los Angeles, California • Santa Monica, California + 9 more

Conditions: Depressive Disorder
Interventions: Mecamylamine hydrochloride (Inversine); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia
Interventions: Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Depressive Disorder, Major
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more

Conditions: Anxiety Disorders
Interventions: sertraline; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 8 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Depression
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions: Lurasidone, FDA Approved antidepressant treatment; Drug
Lead sponsor: George West Mental Health Foundation d/b/a Skyland Trail; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anxiety Disorders, Depressive Disorders, Eating Disorders, Obsessive Compulsive Disorder
Interventions: Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications; Drug
Lead sponsor: Duke University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alcoholism, Alcohol Abuse
Interventions: Citalopram + MI, Placebo + MI; Drug · Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 21 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Depression, Amyotrophic Lateral Sclerosis
Interventions: Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI"); Drug
Lead sponsor: St. Louis University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pain, Total Knee Replacement, Total Hip Replacement
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 79
States / cities: Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more

Conditions: Major Depressive Disorder
Interventions: Standard Clinical Care with an SSRI; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 60 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Irvine, California • La Habra, California • Redlands, California + 19 more

Search by objective public record fields.

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

Biomarkers in the Retina for Prognosticating Mental Health Treatments

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)

Nicotinic Receptor Augmentation of SSRI Antidepressants

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.

Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

Antidepressant Safety in Kids Study

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

SSRIs vs. TCAs for Depression in ALS Patients

Predicting, Understanding and Speeding Recovery After TKA

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Cellular Aging and Neurobiology of Depression Study

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder